My watch list  

8,240 Current news from the industry pharma


You can refine your search further. Select from the filter options on the left to narrow down your results.

New data on Novartis drug Zometa for treatment of breast cancer and multiple myeloma-related bone complications published


Basel, 22 October 2001 – Clinical data published in the September 2001 issue of The Cancer Journal demonstrate that the Novartis drug Zometa (zoledronic acid) reduces the incidence of cancer-related bone complications called skeletal related events (SREs) in patients with multiple myeloma or ...


Novartis submits supplemental NDA with US FDA for Glivec® for treatment of certain GI tumors


Novartis announced today that it has submitted a supplementary New Drug Application (sNDA) to the US Food and Drug Administration (FDA), seeking marketing authorisation for its novel drug Glivec® (imatinib)* for the treatment of patients with unresectable (inoperable) and/or metastatic malignant ...


FDA Public Health Advisory: Update on Use of Doxycycline for Anthrax Exposure


Secretary of Health and Human Services Tommy G. Thompson announced on October 17 in testimony before the Committee on Governmental Affairs and Subcommittee on International Security, Proliferation and Federal Services of the United States Senate, that the Food and Drug Administration is approving ...


D-Pharm Ltd. Raises $30 Million in Private Financing


REHOVOT, Israel Oct. 16, 2001 D-Pharm Ltd., a biopharmaceutical company focused on the rational design and development of innovative drugs for treatment of central nervous system disorders, cancer, and autoimmune diseases, today announced the closing of a $30 million private placement of its ...


Genzyme To Launch Thyrogen® in Europe


Genzyme General, a division of Genzyme Corp., announced October 15 that it will begin marketing Thyrogen® (thyrotropin alfa for injection) in Europe this month. Thyrogen is a recombinant human thyroid stimulating hormone indicated for use in the management of patients being followed up for the ...


FDA Advisory Committee issues split decision on recommendation to approve Diovan® (valsartan) for heart failure indication


Basel / East Hanover, 12 October 2001 – Novartis' Pharmaceuticals affiliate in the US, Novartis Pharmaceuticals Corporation, announced yesterday that the Cardiovascular and Renal Drugs Advisory Committee to the US Food and Drug Administration (FDA) has issued a four-to-four split decision about ...


Alfred Sommer Receives The Bristol-Myers Squibb/Mead Johnson Award For Distinguished Achievement In Nutrition Research


EVANSVILLE, INDIANA (October 12, 2001) -- Alfred Sommer, M.D., M.H.S., is the recipient of the 21st Annual Bristol-Myers Squibb/Mead Johnson Award for Distinguished Achievement in Nutrition Research for his contributions to our understanding of the origin, magnitude and control of nutritional ...


Genzyme Concludes Treat-to-Goal Study


Genzyme General announced on October 11 that it has concluded its Treat-to-Goal clinical trial comparing Renagel® (sevelamer hydrochloride) with calcium-based phosphate binders. At the recommendation of its clinical investigators and its Renagel medical advisory board, Genzyme elected not to ...


bioLeads collaborats with Biofrontera Pharmaceuticals AG


Heidelberg/Leverkusen: bioLeads GmbH and Biofrontera Pharmaceuticals AG announced today that they have entered into a strategic alliance to discover new lead compounds for CNS diseases and develop them to the clinical trials level. The initial focus of the collaboration will be on the medical ...


Myrad Genetics discovers novel anti-cancer drug

Compounds Selectively Activate Programmed Cell Death


Salt Lake City, October 9, 2001 Myriad Genetics, Inc. has discovered a novel drug target for the treatment of a broad range of cancers, and has initiated lead optimization with a series of compounds that selectively kill cancer cells, the Company announced today. The anti-cancer target was ...


Page 824 From 824
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE